BOSTON —

Patients and doctors are bracing as some major insurers get ready to roll out changes to coverage for popular weight loss drugs in Massachusetts.

In January, companies including Blue Cross Blue Shield and Mass General Brigham Health Plan are expected to end coverage for Wegovy and Zepbound.

Those drugs are specifically designed to treat people with obesity. Coverage for diabetes drugs Ozempic and Mounjaro will not be affected.

Doctors say this means patients taking Wegovy and Zepbound could face charges of up to $499 a month rather than standard copays.

"We have many patients who are going to be struggling come the new year to continue on their GLP-1s," said Dr. Caroline Apovian, co-director of the Center for Weight Loss Management and Wellness at Brigham and Women's Hospita

See Full Page